---
title: "Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma | BMY Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288259267.md"
description: "Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma | BMY Stock News"
datetime: "2026-06-01T02:55:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288259267.md)
  - [en](https://longbridge.com/en/news/288259267.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288259267.md)
---

# Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma | BMY Stock News

Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma | BMY Stock News

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.00% on Jun 8: A Full Analysis](https://longbridge.com/en/news/289202504.md)
- [Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock](https://longbridge.com/en/news/288895535.md)
- [BMS secures FDA acceptance for Camzyos sNDA](https://longbridge.com/en/news/288409479.md)
- [Bristol-Myers Upgraded, Broadcom Downgraded: Updated Rankings on Top Blue-Chip Stocks](https://longbridge.com/en/news/289066941.md)
- [04:19 ETLupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma](https://longbridge.com/en/news/288687438.md)